UNSPSC 51284146: Ceftiofur hydrochloride

This classification denotes a cephalosporin antibiotic with the molecular formula C19H17N5O7S3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6822A07436, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((2-furanylcarbonyl)thio)methyl)-8-oxo, monohydrochloride, (6r,7r) but more generally known as ceftiofur hydrochloride, which bears US NIH Compound Identifier 6328657.

UNSPSC 51284146 Ceftiofur hydrochloride is a Commodity code, but the recent opportunities tagged under it do not align with the pharmaceutical active ingredient nominally classified here. Instead, state and local procurement activity under this code shows purchasing of broader health and pharmaceutical products including naloxone, first aid and medical supplies for emergency response, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription fulfillment programs. The scope reflects state health agencies, county health departments, city fire departments, and cooperative purchasing alliances procuring supplies and pharmaceuticals for community health, emergency medical services, and pharmacy benefit management. Issuing bodies span state health commissions (Texas HHS), state cooperative purchasing organizations (Minnesota MMCAP), county governments (Seminole County, Florida), and city departments (Tampa Fire Department).

Activity is geographically dispersed across Florida, Texas, Minnesota, and Oregon, with no dominant regional concentration in recent postings. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the City of Tampa's IFB 26P00145 for 169 line items of medical and first aid supplies for the Fire Department Rescue Division (estimated contract amount $700,000.00, response deadline March 13, 2026, with a 5 percent bid discount available to certified Small Local Business Enterprises); and the Minnesota MMCAP RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products across state and local facilities, with proposals due March 26, 2026. The Texas HHS Commission also issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program, indicating exploratory procurement activity at the state level. The mismatch between the code's nominal scope and actual recent solicitations suggests the tagging reflects a cataloging artifact rather than active pharmaceutical manufacturing ingredient procurement.